Respiree, a health tech company founded in Singapore, has raised US$11.6 million in a series A funding round.

The round was led by We Venture Capital and ClavystBio, with additional participation from Adaptive Capital Partners, Mayo Clinic’s Mayo Foundation for Medical Research, Greenwillow Capital Management, Seeds Capital, and she1K.

The funds will be used to expand Respiree’s commercial operations and enhance its presence in the US, particularly at its headquarters in the Texas Medical Center Innovation in Houston.

The company also aims to strengthen business relationships and improve operations with existing partners.

Respiree’s AI-powered platform focuses on automating patient monitoring and care pathway management.

One of its key AI models, developed in the Mayo Clinic Platform_Accelerate program, seeks to detect patient deterioration earlier and reduce false alarms.

Currently, Respiree operates in the US, Australia, and the Asia-Pacific region, and is exploring expansion into the Gulf Cooperation Council and Thailand.

The company recently partnered with Roche Diagnostics to launch pilot programs across the Asia-Pacific region.